Hi #epitwitter SARSCoV2 attack rate in MA thru Feb 28 is estimated at 24.6% (95% CI: 22.4%-26.3%). It’s difficult to pin this down closer than 3 to 4 percentage points, as there are still several model fits that work well. Underreporting is still at about 3 for Massachusetts. 1/ The Jan 31 estimates had a higher underreporting rate (2.9 to …
Drug-resistance management results presented at two symposia at MIM in Senegal
We presented some of our most recent modeling results on how to effectively manage resistance to multiple artemisinin combination therapies (ACTs) at two symposia at the 7th Multilateral Initiative on Malaria (MIM) Pan-African Malaria Conference. One symposium was run by our partners at Medicines for Malaria Venture (MMV) and a second one was run by Guilin Pharmaceuticals who are awaiting …
eLife selects outstanding papers for 2013
In a bid to shake up the luxury journal cabal, the journal eLife was launched in late 2012 to give researchers a high-quality open-access publishing option that, in addition to having a world-class editorial board, also supports early career scientists and provides open and rigorous peer review. For the second half of 2013, the academic editors of eLife chose five …
The battle against drug resistance just got tougher
Do we have any leverage against drug-resistant organisms? Our post on the Wellcome Trust blog explores the importance of the “fitness cost of drug resistance”. Two studies in 2013 gave notice that our normal expectation — that drug-resistant populations will revert to sensitivity when the selective environment is removed — doesn’t hold true for all pathogens. In mouse and …